Sammenlignet med simvastatin alene eller Tredaptive (2. 000 mg/ 40 mg) alene i 12 uger sænkede Tredaptive (2. 000 mg/ 40 mg) sammen med simvastatin LDL- C (henholdsvis - 47, 9%, - 37, 0%, - 17, 0%), TG (henholdsvis - 33, 3%, - 14, 7%, - 21, 6%), apo B (henholdsvis - 41, 0%, - 28, 8%, - 17, 1%) og TC (henholdsvis - 29, 6%, - 24, 9%, 9, 1%) samt LDL- C: HDL- C (henholdsvis - 57, 1%, - 39, 8%, - 31, 2%), non- HDL- C (henholdsvis - 45, 8%, - 33, 4%, - 18, 1%) og TC: HDL- C (henholdsvis - 43, 0%, - 28, 0%, - 24, 9%) signifikant og øgede HDL- C signifikant (henholdsvis 27, 5%, 6, 0%, 23, 4%).
Tredaptive 2000 mg/ 40 mg administré simultanément avec la simvastatine versus simvastatine seule ou Tredaptive 2000 mg/ 40 mg seul pendant 12 semaines, a induit des diminutions significatives du LDL-C (-47,9%, -37%, -17,0% respectivement), des TG (-33,3%, -14,7%, -21,6% respectivement), des apo B (-1,0%, -28,8%, -17,1% respectivement), et du CT (-29,6%, -24,9%, - 9,1% respectivement), ainsi que du rapport LDL-C/ HDL-C (-57,1%, -39,8%, -31,2% respectivement), du non-HDL-C (-45,8%, -33,4%, -18,1% respectivement) et du rapport CT/ HDL-C (-43,0%, -28,0%, -24,9% respectivement) et augmenté significativement le HDL-C (27,5%, 6,0%, 23,4% respectivement).